Sign inJoin waitlistJoin the waitlist

Julie Voeller

Associate Professor · Baylor College of Medicine

Credentials: · · ·

History

Baylor College of Medicine · University of New Mexico School of Medicine
Present
Baylor College of Medicine
Present

University of Wisconsin School of Medicine and Public Health
2016–2017
Pediatrics
University of Texas Austin Dell Children’s Medical Center
2013–2016
Univ of Texas Southwestern Med Sch at Dallas
2009–2013
Stanford University

Research

Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition
Journal for ImmunoTherapy of Cancer · 2019 · First of 18 authors · 63 citations
Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma
Review · Journal of Pediatric Hematology/Oncology · 2019 · First of 2 authors · 54 citations
Isobaric Labeling Strategy Utilizing 4-Plex N,N-Dimethyl Leucine (DiLeu) Tags Reveals Proteomic Changes Induced by Chemotherapy in Cerebrospinal Fluid of Children with B-Cell Acute…
Journal of Proteome Research · 2020 · 12 citations

CD
Carol Diamond
2 papers
John Maris
2 papers
Paul Sondel
2 papers
TD
Thomas Denapoli
2 papers
Adam Wolfe
1 paper
Andras Heczey
1 paper
Anna Banc-Husu
1 paper
AE
Araceli Elizalde
1 paper
Brian Hickner
1 paper · 1 as a resident
CQ
Carleigh Quillen
1 paper · 1 as a resident
Christian Capitini
1 paper
Clare Twist
1 paper

Clinical trials

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2026–2029
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2030
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2031